Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06487624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 7v6
  2. Study sites: 1 to 6
    • Primary completion date: Aug 31, 2026 to Dec 31, 2026
    • Study completion date: Aug 31, 2026 to May 31, 2027
    • Collaborators expanded, about 2 words
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 30, 2025 to Apr 2, 2025
    v4
  4. Start date: Sep 15, 2024 to Jan 30, 2025v3
  5. Study arms: 1 to 7v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Trial Details
NCT Number NCT06487624
Lead Sponsor FBD Biologics Limited
Collaborators: HanchorBio Inc.
Conditions
(from sponsor)		 Advanced Solid Tumor, Refractory Hodgkin Lymphoma
Related terms Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov